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Significance of Pathophysiology 
Understanding Hereditary Hemochromatosis 
Kari Davidson, RN, BSN,  
Introduction 
     One of the most common genetic diseases, 
hereditary hemochromatosis is a disruption 
of iron regulation in the body.   Its geographic  
distribution  is worldwide, but it is most 
common in those of northern European 
origin.     (Roach and Di Palma, 2012).  
Occurrence is rare in other racial or ethnic 
groups. (Emanuele, Tuason, & Edwards, 
2014).   
       Symptoms are due to significant iron 
overload, normally as a result of HFE gene 
mutation. (Centers for Disease Control and 
Prevention, 2010).   The HFE gene plays an 
important role in regulating iron absorption 
in the GI tract, transport, and storage. 
(Emanuele, et al., 2014).  
      If excess iron accumulates in vital organs, 
cirrhosis, bone and joint disease, diabetes,  
other endocrine disorders and heart disease 
can result. (Crownover & Covey, 2013).   
      Although penetrance (exhibition of 
phenotype, or clinical symptoms) varies in 
those with the genetic mutation, those who 
have the HFE mutation are much more 
genetically susceptible to iron overload as it 
manifests in hereditary hemochromatosis.   
      Patients can present with nonspecific 
complaints such as weakness, fatigue, 
changes in mental status, and arthralgia, so 
hereditary hemochromatosis can be missed 
or misdiagnosed if iron study testing is not  
performed.  The most common route to 
diagnosis is through routine office visits or 
investiation of common complaints. (Brissot, 
Ball, Rofail, Cannon, & We Jin, 2011).      In 
some cases, but not all, genetic testing may be 
appropriate.  Other forms of iron overload 
must be considered as well  when making a 
differential diagnosis.     
    Hereditary hemochromatosis has an 
autosomal recessive pattern; a carrier father 
and carrier mother have a 1 in 4 chance of 
having a homozygous child and a 50% chance 
of having a heterozygous (carrier) child.  
About 75% of homozygotes have expression 
of the disease with elevated serum ferritin 
levels, although there is some controversy as 
to the proportion which develops clinically 
significant disease.  Environmental and 
genetic factors may interact to influence 
expression of hereditary 
hemochromatosis.(Roach & DiPalma,2012).  
Approximately 1 million people in the United 
States are homozygous for the mutation. 
(National Heart Lung and Blood Institute, 
2011).   According to Emauele, et al., (2014), 
1 in 8 to 1 in 10 whites in the United States 
may be carriers of the affected HFE gene.   
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Figure 1. The hand on the right shows hyperpigmentation, or 
bronzing of the skin, due to iron overload in  hereditary 
hemochromatosis. 
Image Courtesy of Consultant 360.com 
Figure 2. Normal HFE Gene Compared to C282Y Mutation in Hemochromatosis Type 1 
www.CDC.gov 
• Slow progression.   Many are asymptomatic.   
 
• Age of presentation typically 40-60 in men, post-
menopause in women. 
 
• Early signs and symptoms tend to be general and 
may include:  
• Weight loss 
• Fatigue  
• Joint discomfort 
• Abdominal discomfort 
• Weakness  
• Restless leg syndrome 
• Hair loss 
• Loss of libido 
• Changes in mental status/depression 
(Rojas-Roldan & Wilkins, 2014). 
 
• With untreated advanced disease, patients may 
present with: 
• Hepatitis 
• Hepatomegaly 
• Hepatocellular cancer  
• Cirrhosis  
• Arrhythmias 
• Arthritis, particularly of the second or 
third metacarpophalangeal joints. 
• Cardiomyopathy 
• Bronzed, hyperpigmented skin 
• Diabetes Mellitus 
• Hypogonadism  
   
• Laboratory findings: 
• Transferrin Saturation >45% 
• Serum ferritin levels > 300 ng/mL  
• Serum ferritin >200 in 
premenopausal females 
 (Centers for Disease Control and 
Prevention, 2010).  
 
 
 
 
 
 
 
 
    
     Hereditary hemochromatosis encompasses a range of iron overload disorders 
which are due to genetic misregulation of iron acquisition. (Vujic, 2014).   
     The specific mutation which accounts for most cases of hereditary 
hemochromatosis occurs at  the major histocompatibility complex (MHC) region 
on the short arm of chromosome 6.  A missense mutation is found at this locus in 
80% of hereditary hemochromatosis patients.   The mutation results in a cysteine 
to tyrosine substitution at amino acid 282 of the HFE protein (C282Y).  (Vujic, 
2014).  This form of the disease is known as “hemochromatosis type 1”.  
(Cherfane, Hollenbeck, Go, & Brown, 2013).  
     
     Normally, hepatocytes secrete the regulatory hormone hepcidin in response to excess 
iron intake.  Hepcidin, a peptide hormone, decreases intestinal iron absorption by 
enterocytes and decreases iron release by macrophages, contributing to whole-body 
iron homeostasis. The HFE genetic defect alters expression of the protein which 
regulates hepcidin.  (Crownover and Covey, 2013).  Patients with hereditary 
hemochromatosis have insufficient hepcidin concentrations, resulting in unregulated 
iron absorption, mobilization, distribution, and storage. (Emanuele, et al., 2014).   A 
major means of iron export from the body is the ferroportin-hepcidin pathway.  
Hepcidin binds with ferroportin, which is located on enterocytes (GI tract), 
macrophages, and hepatocytes, and regulates release of cellular iron.  This pathway is 
disrupted due to low hepcidin levels.  (Emanuele, et al., 2014).  
     Iron begins to enter the plasma at a high rate, leading to increased transferrin 
saturation and ferritin levels, and over time builds up in body tissues and organs, 
causing damage.  (Emanuele, et al., 2014).  Major organs adversely affected by iron 
deposition are the liver, pancreas, heart, pituitary gland, testicles, joints, and skin.  Many 
of the presenting signs and symptoms are due to disruption of the  normal function of 
these organs.   
      Main pathological findings in the liver are fibrosis and cirrhosis.  Iron overload  may 
contribute to the risk of diabetes, as it is associated with increased hepatic glucose 
production and metabolic inflexibility, both characteristics of type II diabetes. (Huang, et 
al., 2011).   
     Less common forms of hereditary hemochromatosis (types 2-4) are caused by 
mutations in genes other than HFE which help control iron regulation.   (Cherfane, et al., 
2013).  A less common form of the type 1 mutation is at H63D, another locus of the HFA 
gene.   Compound heterozygotes (those carrying the C282Y defect and another 
autosomal recessive mutation which could affect iron regulation) are susceptible to 
developing iron overload. accounting in part for variability in expression.  Non-genetic 
factors such as alcoholism may contribute to disease progression.   
     Iron is “essential for cell metabolism and is a constituent of hemoproteins, such as 
hemoglobin, myoglobin, and cytochrome.” (Crownover & Covey, 2013, p. 183).   Any 
pathological process which disrupts the carefully regulated iron balance of the body 
will eventually affect entire body systems.   Hereditary hemochromatosis, with an 
insidious onset and often generalized presenting systems, could slide under the radar 
or be misdiagnosed until  more severe manifestations of iron overload appear.   End-
organ damage or clinical manifestations of hereditary hemochromatosis occur in 
approximately 10 percent of persons homozygous for C282Y. (Crownover & Covey, 
2013).   Considering the number of those homozygous for the disease, this is a  
significant portion of the population. 
    Hereditary hemochromatosis is associated with an increased risk for malignancies, 
such as hepatocarcinoma and breast cancer.  “Approximately 6 percent of patients 
with hemochromatosis and cirrhosis develop hepatocellular carcinoma; this 
represents a 20-fold increased lifetime risk over the general population…”  
(Crownover & Covey, 2013, p. 183).    
    If untreated, hereditary hemochromatosis can lead to irreversible organ damage. 
Prognosis is worsened in those who develop cirrhosis, diabetes, or cardiomyopathy. 
“The 5-year survival rate in those who have untreated hereditary hemochromatosis 
and cirrhosis is reduced by 50 percent compared with those who do not have 
cirrhosis.” (Crownover & Covey, 2013, p. 184.) 
     It is important to understand the progression of the disease, the broad spectrum of 
phenotypical expression, and the underlying genetic, hormonal, and environmental 
interplay at work in this disease in order to recognize and anticipate how body 
systems may be affected. 
     
 
     Although patients may rarely present with the 
classic triad of symptoms described by Trousseau 
(bronzed skin, diabetes mellitus, and 
hepatomegaly), practitioners should also consider 
hereditary hemochromatosis in patients with 
nonspecific symptoms such as fatigue, arthralgia, 
weakness, cognition changes, or depression in 
conjunction with elevated transferrin saturation 
and ferritin levels.   Medical professionals should 
be aware that expression of the disease is 
influenced not only by genetics but also by other 
factors such as alcoholism, iron rich diet, 
menstruation,  age, and other diseases of iron 
malabsorption such as celiac disease.  
     If a patient is of northern European ancestry, 
this genetic disorder may be of particular concern 
in those with relevant symptoms. 
     There is debate among researchers about the 
usefulness of genetic testing.  Population screening 
for the HFE mutation is not recommended by the 
Centers for Disease Control and Prevention, but 
should be performed in first degree relatives of 
those with HFE hemochromatosis. (Crownover & 
Covey, 2013).  According to the Centers for Disease 
Control and Prevention, iron status testing is 
considered more clinically relevant than genetic 
testing for identifying those who have 
hemochromatosis (2010).    Many times this 
disease is diagnosed in patients after routine office 
visits, so general practitioners should be aware of 
its nuances.  
     
     
 
    Hereditary hemochromatosis 
is the most common genetic 
disorder affecting whites in the 
United States.  Most of those 
who are homozygous for the 
mutation are asymptomatic.         
Manifestation of symptoms 
correlates with body iron 
content, with symptoms 
worsening as iron levels 
increase.   At the beginning of 
disease progression, patients 
may have nonspecific 
complaints, but may progress 
to signs of organ damage and 
early death.    
     Treatment for iron overload 
in hereditary hemochromatosis 
includes decreasing dietary 
iron intake and phlebotomy to 
decrease serum ferritin to the 
desired level. It is imperative 
that health practitioners know 
how to recognize and respond 
to hereditary hemochromatosis, 
preferably before irreversible 
organ damage occurs.  
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